Svetislava J. Vukelja

7.4k total citations · 3 hit papers
83 papers, 5.2k citations indexed

About

Svetislava J. Vukelja is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Svetislava J. Vukelja has authored 83 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 24 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Svetislava J. Vukelja's work include Cancer Treatment and Pharmacology (34 papers), Breast Cancer Treatment Studies (22 papers) and HER2/EGFR in Cancer Research (20 papers). Svetislava J. Vukelja is often cited by papers focused on Cancer Treatment and Pharmacology (34 papers), Breast Cancer Treatment Studies (22 papers) and HER2/EGFR in Cancer Research (20 papers). Svetislava J. Vukelja collaborates with scholars based in United States, United Kingdom and Mexico. Svetislava J. Vukelja's co-authors include Joyce O’Shaughnessy, Hope S. Rugo, Stephen E. Jones, Kimberly Blackwell, José Baselga, Joachim Bischoff, Anna Maria Storniolo, George W. Sledge, Catherine Ellis and Harold J. Burstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Svetislava J. Vukelja

81 papers receiving 5.0k citations

Hit Papers

Superior Survival With Capecitabine Plus Docetaxel Combin... 2002 2026 2010 2018 2002 2010 2010 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
    2002 855 citations Joyce O’Shaughnessy, David Miles et al. Journal of Clinical Oncology profile →
  2. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
    2010 701 citations Kimberly Blackwell, Harold J. Burstein et al. Journal of Clinical Oncology profile →
  3. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
    2010 568 citations Hope S. Rugo, Svetislava J. Vukelja et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Svetislava J. Vukelja United States 30 4.2k 1.5k 1.0k 954 697 83 5.2k
Francis P. Worden United States 49 3.5k 0.8× 1.4k 1.0× 644 0.6× 2.3k 2.4× 1.7k 2.5× 257 9.1k
M. Kaufmann Germany 41 3.6k 0.8× 2.5k 1.7× 469 0.5× 828 0.9× 1.6k 2.3× 242 6.5k
Jacob Schachter Israel 47 6.5k 1.5× 748 0.5× 358 0.4× 857 0.9× 3.0k 4.3× 189 8.4k
Dimitrios Pectasides Greece 43 2.9k 0.7× 700 0.5× 493 0.5× 1.2k 1.3× 1.7k 2.4× 227 6.1k
Emina Torlakovic Canada 33 3.6k 0.9× 1.1k 0.8× 444 0.4× 2.0k 2.1× 1.1k 1.6× 139 5.9k
Megan L. Troxell United States 36 1.5k 0.4× 699 0.5× 556 0.5× 1.2k 1.3× 1.3k 1.8× 141 4.3k
Jean‐Pierre Delord France 43 5.5k 1.3× 1.1k 0.8× 431 0.4× 2.0k 2.1× 2.2k 3.2× 260 8.4k
Lance C. Pagliaro United States 41 2.1k 0.5× 1.0k 0.7× 534 0.5× 2.4k 2.5× 1.6k 2.2× 199 5.9k
Evan J. Lipson United States 41 5.9k 1.4× 642 0.4× 440 0.4× 1.6k 1.7× 1.4k 2.0× 126 7.7k
Edward H. Romond United States 25 2.9k 0.7× 1.5k 1.0× 1.1k 1.1× 639 0.7× 519 0.7× 61 3.9k

Countries citing papers authored by Svetislava J. Vukelja

Since Specialization
Citations

This map shows the geographic impact of Svetislava J. Vukelja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svetislava J. Vukelja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svetislava J. Vukelja more than expected).

Fields of papers citing papers by Svetislava J. Vukelja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svetislava J. Vukelja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svetislava J. Vukelja. The network helps show where Svetislava J. Vukelja may publish in the future.

Co-authorship network of co-authors of Svetislava J. Vukelja

This figure shows the co-authorship network connecting the top 25 collaborators of Svetislava J. Vukelja. A scholar is included among the top collaborators of Svetislava J. Vukelja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svetislava J. Vukelja. Svetislava J. Vukelja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Shaughnessy, Joyce, Hartmut Koeppen, Yuanyuan Xiao, et al.. (2015). Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clinical Cancer Research. 21(19). 4305–4311. 37 indexed citations
2.
Edenfield, William J., Donald Richards, Svetislava J. Vukelja, et al.. (2014). A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). 8068–8068. 15 indexed citations
3.
Paul, Devchand, Scot Sedlacek, Anne Favret, et al.. (2013). Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. The Lancet Oncology. 14(11). 1121–1128. 92 indexed citations
4.
Blackwell, Kimberly, Harold J. Burstein, Anna Maria Storniolo, et al.. (2012). Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. Journal of Clinical Oncology. 30(21). 2585–2592. 411 indexed citations
5.
Blackwell, Kimberly, Harold J. Burstein, Anna Maria Storniolo, et al.. (2010). Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology. 28(7). 1124–1130. 701 indexed citations breakdown →
6.
Jones, Stephen E., Frankie A. Holmes, Joyce O’Shaughnessy, et al.. (2009). Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. Journal of Clinical Oncology. 27(8). 1177–1183. 400 indexed citations
7.
Osborne, Cynthia R., Scot Sedlacek, Devchand Paul, et al.. (2009). The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer. Breast Cancer Research and Treatment. 116(3). 521–527. 8 indexed citations
8.
Loesch, David, Lina Asmar, Kristi McIntyre, et al.. (2008). Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer. Clinical Breast Cancer. 8(2). 178–186. 24 indexed citations
9.
Blum, Joanne L., Elizabeth Claire Dees, Svetislava J. Vukelja, et al.. (2007). Phase II Trial of Capecitabine and Weekly Paclitaxel in Patients with Metastatic Breast Cancer Previously Treated with Every-3-Week Taxane Therapy. Clinical Breast Cancer. 7(6). 465–470. 21 indexed citations
10.
Nemunaitis, John, Neil Senzer, Casey Cunningham, et al.. (2006). Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer. Molecular Therapy. 13(6). 1185–1191. 53 indexed citations
11.
Nemunaitis, John, Casey Cunningham, Neil Senzer, et al.. (2004). A phase 1 trial of PT-100 in patients receiving myelosuppressive chemotherapy. Journal of Clinical Oncology. 22(14_suppl). 2572–2572. 1 indexed citations
12.
Asmar, Lina, James Cantrell, Svetislava J. Vukelja, et al.. (2004). A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study. Journal of Clinical Oncology. 22(14_suppl). 516–516. 8 indexed citations
13.
Holmes, Frankie A., Stephen E. Jones, Joyce O’Shaughnessy, et al.. (2002). Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer. Annals of Oncology. 13(6). 903–909. 241 indexed citations
14.
Miles, David, J. O’Shaughnessy, Guadalupe Cervantes, et al.. (2001). Survival benefit with Xeloda (capecitabine)/docetaxel vs docetaxel: analysis of post-study therapy.. Breast Cancer Research and Treatment. 69(3). 287–287. 12 indexed citations
15.
Vukelja, Svetislava J., et al.. (1994). Arsenic Intoxication Presenting with Macrocytosis and Peripheral Neuropathy, without Anemia. Acta Haematologica. 92(3). 142–143. 9 indexed citations
16.
Baker, William J., et al.. (1994). Multicentric angiofollicular lymph node hyperplasia and associated carcinoma. Medical and Pediatric Oncology. 22(6). 384–388. 1 indexed citations
17.
Vukelja, Svetislava J., et al.. (1992). Nonbacterial Thrombotic Endocarditis Clinically Mimicking Veno-Occlusive Disease of the Liver Complicating Autologous Bone Marrow Transplantation. American Journal of Clinical Oncology. 15(6). 500–502. 9 indexed citations
18.
Vukelja, Svetislava J., et al.. (1990). Enlargement of mediastinal masses on simulation films: A radiotherapeutic problem in the management of patients with Hodgkin's disease. Medical and Pediatric Oncology. 18(1). 44–48. 1 indexed citations
19.
Vukelja, Svetislava J., S. John Swanson, Robert Knight, & Raymond B. Weiss. (1989). Testicular relapse in adult acute lymphocytic leukemia: A case report and literature review. Medical and Pediatric Oncology. 17(2). 170–173. 5 indexed citations
20.
Vukelja, Svetislava J., Raymond B. Weiss, David J. Perry, & Dan L. Longo. (1988). Eosinophilia associated with adult t-cell leukemia/lymphoma. Cancer. 62(8). 1527–1530. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francis P. Worden Breakdown of academic impact, for papers by M. Kaufmann Breakdown of academic impact, for papers by Jacob Schachter Breakdown of academic impact, for papers by Dimitrios Pectasides Breakdown of academic impact, for papers by Emina Torlakovic Breakdown of academic impact, for papers by Megan L. Troxell Breakdown of academic impact, for papers by Jean‐Pierre Delord Breakdown of academic impact, for papers by Lance C. Pagliaro Breakdown of academic impact, for papers by Evan J. Lipson Breakdown of academic impact, for papers by Edward H. Romond
Rankless by CCL
2026